

<b>Patient Name</b> SAMPLEREPORT,JAK2M	<b>Patient ID</b> SA00067487	<b>Age</b> 47	<b>Gender</b> F	<b>Order #</b> SA00067487
<b>Ordering Phys</b> CLIENT,CLIENT				<b>DOB</b> 06/10/1966
<b>Client Order #</b> SA00067487	<b>Account Information</b>			<b>Report Notes</b>
<b>Collected</b> 05/14/2014 00:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
<b>Printed</b> 05/15/2014 14:52	Rochester, MN 55901			

Test	Flag Results	Unit	Reference Value	Perform Site*
------	--------------	------	-----------------	---------------

**JAK2 V617F Mutation Detection, BM**

MCR

Bone marrow, JAK2 V617F mutation analysis:

Positive. JAK2 V617F mutated DNA was detected and measured at 20% of total JAK2 DNA.

JAK2V617F mutation is found with high frequency in Philadelphia chromosome-negative myeloproliferative neoplasms (>95% in polycythemia vera and approximately 50-60% in primary myelofibrosis and essential thrombocythemia). It can also occur in other myeloid neoplasms, such as refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and rarely in myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and acute myeloid leukemia. Clinicopathologic correlation is recommended for a definitive diagnosis.

The precision of JAK2 mutation percentage measurement is such that values 2 times higher or lower than the reported value are considered equivalent.

Signing Pathologist: Melissa Tricker-Klar

Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.01% (see Mayo Medical Laboratories Interpretive Handbook for method details).

Laboratory developed test.

PDF Report available at:

<https://test.mmlaccess.com/Reports/C7028846-juiolARnQk.ashx>
**RECEIVED:** 05/15/2014 10:20 **REPORTED:** 05/15/2014 14:10

\* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:
-----	-----------------------------------------------------------------------------------------	---------------

<b>Patient Name</b> SAMPLEREPORT,JAK2M	<b>Collection Date and Time</b> 05/14/2014 00:00	<b>Report Status</b> Final
Page 1 of 1		** End of Report **

\* Report times for Mayo performed tests are CST/CDT

**Performing Site:**

Mayo Clinic Laboratories - Rochester Main Campus  
200 First Street SW, Rochester MN 55905  
Franklin R. Cockerill, M.D. Lab Director  
Phone: 800-533-1710  
<http://www.mayomedicallaboratories.com>

**SAMPLEREPORT, JAK2M**

**MEDICAL RECORD # (PATIENT ID) SA00067487**

<b>DOB</b>	06/10/1966	<b>CLIENT ID/WARD</b>	7028846	<b>ORDER #</b>	C215000229
<b>SEX</b>	Female	<b>CLIENT/NAME WARD</b>	DLMP Rochester	<b>CLIENT ORDER #</b>	SA00067487
<b>CLIENT MRN</b>	SA00067487	<b>CITY, ST, ZIP</b>	Rochester	<b>DATE COLLECTED</b>	5/14/2014 12:00 AM
<b>REQUESTED BY</b>	CLIENT CLIENT		MN 55901	<b>DATE RECEIVED</b>	5/15/2014 10:20 AM
				<b>DATE REPORTED</b>	5/15/2014 2:10 PM

**JAK2 V617F Mutation Detection, BM**

**Interpretation**

Bone marrow, JAK2 V617F mutation analysis:

Positive. JAK2 V617F mutated DNA was detected and measured at 20% of total JAK2 DNA.

JAK2V617F mutation is found with high frequency in Philadelphia chromosome-negative myeloproliferative neoplasms (>95% in polycythemia vera and approximately 50-60% in primary myelofibrosis and essential thrombocythemia). It can also occur in other myeloid neoplasms, such as refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and rarely in myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and acute myeloid leukemia. Clinicopathologic correlation is recommended for a definitive diagnosis.

The precision of JAK2 mutation percentage measurement is such that values 2 times higher or lower than the reported value are considered equivalent.

Sig n i n q Pathol o g i s t: M e l i s s a T r i c k e r - K l a r

**Method:**

Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.01% (see Mayo Medical Laboratories Interpretive Handbook for method details).

**Disclaimer:**

Laboratory developed test.

Site ID: C7028846

Accession Number: SA00067487

FileName: SA00067487-7WKfNO

+py219z9P11FbY7uzlh7VOCwh2gYo\_tJABi9nxMINer6Qv9MdozwDIuQyaszHjv2DcnY75y9GVDkKgg==.pdf

Reported Date & Time: 05/15/14 14:13

Test Name: JAK2 V617F Mutation Detection, BM

Result Name: JAK2 V617F Mutation Detection, BM